Born: 1950 Title: Member of the Board since 2018.
Education: PhD at Uppsala University.
Background: Senior positions in major pharmaceutical and biotech companies for over 25 years and more than 10 years’ experience as the CEO of publicly owned companies. As the CEO of ACADIA Pharmaceuticals from 2000−2015, he led its development from a private start-up to a public, multibillion dollar company. In the 1990s, he held senior positions at Astra AB, prior to which he was a Professor of Organic Chemistry at Uppsala University.
Other directorships: Member of the Boards of Active Biotech, InDex Pharmaceuticals AB and Beactica AB.
Shares in Medivir: 49,000 class B shares.
Born: 1956 Title: Member of the Board since 2018.
Education: Ph.D. in Genetics from Umeå University.
Background: Extensive experience of pharmaceutical and commercial development in senior positions with both biotech and pharmaceutical companies, such as KabiGen AB, Symbicom AB, AstraZeneca, and Biovitrum AB, and as CEO of Arexis AB. Responsible for Industrifonden’s life science operations from 2008 to 2016, and currently working as a senior advisor to the fund on a consultancy basis. He has held seats on the Boards of over 30 companies and is also a co-founder of two pharmaceutical development companies.
Other directorships: Member of the Boards of InDex Pharmaceuticals AB and Calliditas Therapeutics AB. Chairman of the Boards of Cinclus Pharma Holding AB, Ignitus AB and Sixera Pharma AB.
Shares in Medivir: 10,000 class B shares.
Born: 1953
Title: Member of the Board since 2017.
Education: M. Sc. Pharmacy. Has worked in the pharmaceutical industry since 1978.
Background: CEO of Linc AB, which invests in life sciences. Since 1990, primarily active as an investor in and a Member of the Boards of pharmaceutical development companies. Experience of developing and commercialising products.
Other directorships: Member of the Boards of Linc AB, Livland Skog AB, Knil AB, Calliditas Therapeutics AB, Animal Probiotics AB, Rejson AB, Sedana Medical AB, Stille AB and Swevet AB, and a number of smaller companies.
Shares in Medivir: 1,008,283 class B shares (through an insurance solution).
Born: 1957
Title: Chairman of the Board. Member of the Board since 2015.
Education: B.Sc. in Economics and Business Administration from the Stockholm School of Economics
Background: Extensive experience of the financial and equity markets and of corporate governance issues. Previous employed by Neonet, Odin Förvaltning, Nordea Asset Management and SEB Asset Management, amongst others.
Other directorships: Founder and now Chairman of the Board of Nordic Investor Services AB. Member of the Boards of Concordia Maritime AB, Lannebo Fonder, Recipharm AB, Rejlers and Stendörren Fastigheter. Chairman of the Board of Ativo Finans.
Shares in Medivir, including family: 53,750 class B shares.
Born: 1960
Title: Member of the Board since 2019.
Education: M.D. Erasmus University, Rotterdam.
Background: An has a long experience of industrial drug development and has held several executive management positions within Clinical Development, Medical Affairs, Business Development and Commercial at Pharmacia and Swedish Orphan Biovitrum in Sweden, Eli Lilly in Holland, Roche in USA and Switzerland. Previous experience from, Biotech and start-up companies. She has a broad expertise in Global Development and Clinical Operations. She is an entrepreneur and also a professional coach.
Other directorships: Member of the Board of BioInvent International AB, Savara Pharmaceuticals Inc., PLUS Therapeutics and Agendia BV.
Shares in Medivir: 0.
Born: 1945
Title: Member of the Board since 2017.
Education: Professor of Tumour Biology at Uppsala University, the Faculty of Medicine, since 1986.
Background: Dean of the Faculty of Medicine at Uppsala University, 1996-2002, and Vice-Rector of Medicine and Pharmacy, 1999-2002. Chairman of the research board of the Swedish Cancer Society, 2003-2013. He has published over 300 papers in scientific journals, primarily on the mechanisms governing the uncontrolled growth of cancer cells. Member of the Royal Swedish Academy of Sciences, the European Molecular Biology Organisation, and the European Academy of Cancer Sciences. He has received a number of prizes and awards for his research and has been cited over 25,000 times by other researchers.
Other directorships: Member of the Board of Hamlet Pharma AB and several advisory groups for medical research financing.
Shares in Medivir: 8,000 class B shares.